Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma

被引：0

作者：

Martin, Thomas ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Mikhael, Joseph ^{[3
]}

Yong, Kwee ^{[4
]}

Capra, Marcelo ^{[5
]}

Facon, Thierry ^{[6
]}

Hajek, Roman ^{[7
,8
]}

Spicka, Ivan ^{[9
]}

Casca, France ^{[10
]}

Mace, Sandrine ^{[11
]}

Risse, Marie-Laure ^{[12
]}

Moreau, Philippe ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Hematol, San Francisco, CA USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[3] Translat Genom Res Inst, City Hope Canc Ctr, Phoenix, AZ USA

[4] Univ Coll Hosp, Dept Hematol, London, England

[5] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[6] Lille Univ Hosp, Dept Hematol, Lille, France

[7] Univ Ostrava, Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[8] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[9] Charles Univ & Gen Hosp, Ist Fac Med, Dept Hematol, Dept Med, Prague, Czech Republic

[10] Ividata Life Sci Contracted Sanofi, Levallois Perret, France

[11] Sanofi R&D Translat Med, Chilly Mazarin, France

[12] Sanofi R&D, Vitry Sur Seine, France

[13] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

MM; IKEMA; isatuximab; multiple myeloma; progression-free survival; Phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-064

引用

页码：S403 / S404

页数：2

共 50 条

[31] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Meletios Dimopoulos
Michael Wang
Vladimir Maisnar
Jiri Minarik
William Bensinger
Maria-Victoria Mateos
Mihaela Obreja
Julie Blaedel
Philippe Moreau
Journal of Hematology & Oncology, 11
[32] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
Dimopoulos, Meletios A.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David S.
Weisel, Katja
Gavriatopoulou, Maria
Oriol, Albert
Rabin, Neil K.
Nooka, Ajay
Qi, Ming
Ding, Bifeng
Zahlten-Kumeli, Anita
Usmani, Saad Z.
BLOOD, 2020, 136
[33] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Dimopoulos, Meletios
Wang, Michael
Maisnar, Vladimir
Minarik, Jiri
Bensinger, William
Mateos, Maria-Victoria
Obreja, Mihaela
Blaedel, Julie
Moreau, Philippe
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[34] Isatuximab in combination with carfilzomib and dexamethasone in 1q21+patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole M.
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
HEMATOLOGICAL ONCOLOGY, 2024, 42 (02)
[35] Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning
Dimopoulos, Meletios Athanasios
Landgren, Ola
Siegel, David S.
Grosicki, Sebastian
Oriol, Albert
Najdi, Rani
Li, Chuang
Mezzi, Khalid
Shu, Natalie
Quach, Hang
BLOOD, 2023, 142
[36] Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies
Quach, Hang
Nooka, Ajay
Samoylova, Olga
Venner, Christopher
Kim, Kihyun
Facon, Thierry
Spencer, Andrew
Usmani, Saad
Grosicki, Sebastian
Suzuki, Kenshi
Delimpasi, Sosana
Weisel, Katja
Obreja, Mihaela
Zahlten-Kumeli, Anita
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S294 - S294
[37] Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma
Vij, Ravi
Wang, Michael
Jagannath, Sundar
Niesvizky, Ruben
Jakubowiak, Andrzej J.
Kavalerchik, Edward
Huang, Mei
Siegel, David S.
LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2959 - 2961
[38] Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.
Orlowski, Robert Z.
Moreau, Philippe
Ludwig, Heinz
Rocafiguera, Albert Oriol
Chng, Wee Joo
Goldschmidt, Hartmut
Yang, Zhao
Kimball, Amy
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[39] Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.
Maiese, Eric
Graham, Christopher N.
Hawe, Emma
Le Moine, Jean-Gabriel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
Richardson, Paul
Wolf, Jeffrey Lee
Jakubowiak, Andrzej
Zonder, Jeffrey A.
Lonial, Sagar
Irwin, David H.
Krishnan, Amrita
Densmore, John
Raje, Noopur
Bar, Michael H.
Schlossman, Robert L.
Ghobrial, Irene
Munshi, Nikhil C.
Martin, Thomas
Laubach, Jacob
Allerton, Jeffrey P.
Hideshima, Teru
Gardner, Lesa
Sportelli, Peter
Anderson, Kenneth C.
BLOOD, 2009, 114 (22) : 741 - 742

← 1 2 3 4 5 →